Trevena (NASDAQ:TRVN – Get Free Report) is expected to be announcing its resultson Thursday, November 5th. Analysts expect the company to post earnings of ($50.00) per share and revenue of $0.78 million for the quarter.
Trevena Trading Up 2,120.0%
Shares of NASDAQ:TRVN opened at $0.01 on Thursday. The company has a fifty day simple moving average of $0.01 and a 200 day simple moving average of $0.01. The firm has a market cap of $10,644.90, a PE ratio of -0.00 and a beta of -1.99. Trevena has a 12-month low of $0.00 and a 12-month high of $1.50.
About Trevena
Trevena, Inc is a biopharmaceutical company focused on developing medicines for central nervous system disorders, with an emphasis on addressing the limitations of existing opioid and other neurological therapies. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena’s principal commercial product is OLINVYK (oliceridine) injection, an intravenous opioid approved by the U.S. Food and Drug Administration for the management of acute pain in adults severe enough to require an intravenous opioid analgesic.
Recommended Stories
- Five stocks we like better than Trevena
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
